Cancer Urology最新文献_第3页

Stent-ception: implementation of soft double-J stents in the ureteric Memokath-051TM in bilateral ureteric stricture post radiotherapy for advanced prostate cancer 支架截取：在晚期前列腺癌放疗后双侧输尿管狭窄中使用输尿管软双 J 支架 Memokath-051TM

Cancer Urology Pub Date : 2023-11-16 DOI: 10.17650/1726-9776-2023-19-3-100-103

M. F. Mohd, M. D. M. Ashraf, M. R. Yusof, N. G. Faiz, Siti Rahmah, H. Merican, Dr Mohamed Ashraf Bin, Mohamed Daud

{"title":"Stent-ception: implementation of soft double-J stents in the ureteric Memokath-051TM in bilateral ureteric stricture post radiotherapy for advanced prostate cancer","authors":"M. F. Mohd, M. D. M. Ashraf, M. R. Yusof, N. G. Faiz, Siti Rahmah, H. Merican, Dr Mohamed Ashraf Bin, Mohamed Daud","doi":"10.17650/1726-9776-2023-19-3-100-103","DOIUrl":"https://doi.org/10.17650/1726-9776-2023-19-3-100-103","url":null,"abstract":"Narrowing of ureter can be due to malignant or benign causes. Temporary double-J (DJ) stents, various metallic stent designs, or definitive corrective surgery can be the options management for ureteric stricture. As an alternative from DJ stents, Memokath-051TM (MMK-051TM) can be inserted in strictured ureters post radiotherapy for advanced prostate cancer patients. We present a case of an advanced prostate cancer which bilateral DJ Stents placed within MMK-051TM. A 76-year-old man with underlying hormone sensitive advanced prostate cancer completed radiotherapy. Post radiotherapy he developed bilateral ureteric strictures and bilateral DJ stents inserted. He had to underwent multiple change of stents due to blockage. Patient had MMK-051TM inserted, however complicated with blockage due to encrustation. Improvisation method done by putting the bilateral DJ stents within the MMK-051TM. Patient had no more blockage of MMK-051TM after the placement of DJ stents within it. However, patient succumbed to death a year after the last procedure. Our case report highlighted encrustation of metallic ureteric stents and a novel approach to overcome this problem. Introduction of additional DJ stents not only reduced the incidence of MMK-051TM blockage but also improved the quality of life of the patient.","PeriodicalId":216890,"journal":{"name":"Cancer Urology","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139269469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metanephric adenoma of the kidney: clinical case and literature review 肾积水腺瘤：临床病例和文献综述

Cancer Urology Pub Date : 2023-11-16 DOI: 10.17650/1726-9776-2023-19-3-119-125

E. V. Grebenkin, A. Pshikhachev, B. E. Osmolovskiy, A. A. Epishkina, E. Y. Kozhevnikova, N. I. Sorokin, A. A. Kamalov

引用次数: 0

The prevalence of malignant neoplasms of the kidney in Saint Petersburg and various regions of Russia in 2016-2021 2016-2021 年圣彼得堡和俄罗斯各地区肾脏恶性肿瘤的发病率

Cancer Urology Pub Date : 2023-11-16 DOI: 10.17650/1726-9776-2023-19-3-163-174

S. Popov, R. Guseynov, I. Orlov, V. Khizha, A. N. Yazenok, K. Sivak, V. V. Perepelitsa, N. S. Bunenkov, A. S. Ulitina

{"title":"The prevalence of malignant neoplasms of the kidney in Saint Petersburg and various regions of Russia in 2016-2021","authors":"S. Popov, R. Guseynov, I. Orlov, V. Khizha, A. N. Yazenok, K. Sivak, V. V. Perepelitsa, N. S. Bunenkov, A. S. Ulitina","doi":"10.17650/1726-9776-2023-19-3-163-174","DOIUrl":"https://doi.org/10.17650/1726-9776-2023-19-3-163-174","url":null,"abstract":"Background. Currently, kidney cancer remains one of the most common oncourological diseases with relatively high mortality rate.Aim. To study the main epidemiological indicators of malignant neoplasms of the kidney in various regions of Russia and Saint Petersburg.Materials and methods. Based on the data from the Department of Medical Statistics of Tumor Diseases of the Medical Information and Analytical Center, the epidemiological indicators of malignant neoplasms of the kidney for the period between 2016 and 2021 in Russia, individual Federal Districts of the country and Saint Petersburg were analyzed.Results. Despite the increase in the prevalence of malignant neoplasms of the kidney, medical oncological care for the population is at an appropriate level. Most cases of the disease are diagnosed at early stages, there is a decrease in patient mortality rates and an increase in 5-year survival, which indicates the effectiveness of ongoing anticancer measures. In a number of Federal Districts, a number of indicators showed a negative trend compared to the all-Russia data, which requires close attention.Conclusion. The analysis of statistical data of patients with malignant neoplasms of the kidney can be used to optimize the algorithms for diagnosing and treating this category of patients, as well as to improve oncological care for the population.","PeriodicalId":216890,"journal":{"name":"Cancer Urology","volume":"60 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139268981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pathogenic BRCA2 c.6341del gene variant in a patient with prostatic cancer from the North Ossetia 北奥塞梯一名前列腺癌患者的致病性 BRCA2 c.6341del 基因变异

Cancer Urology Pub Date : 2023-11-16 DOI: 10.17650/1726-9776-2023-19-3-94-99

M. B. Bolieva, O. Brovkina, D. S. Khodyrev, A. G. Nikitin, A. A. Epkhiev, L. M. Voronkova, M. Gordiev

引用次数: 0

Surgical access in treatment of kidney cancer complicated by tumor thrombosis of the inferior vena cava and right atrium 下腔静脉和右心房肿瘤血栓形成并发肾癌治疗的手术通路

Cancer Urology Pub Date : 2023-11-16 DOI: 10.17650/1726-9776-2023-19-3-146-152

R. N. Komarov, L. Rapoport, M. Shao, M. I. Tkachev, B. M. Tlisov, A. V. Zavaruev, A. Simonyan

引用次数: 0

Nephrotoxicity of combination drug therapy in metastatic renal cancer 转移性肾癌联合药物治疗的肾毒性

Cancer Urology Pub Date : 2023-11-16 DOI: 10.17650/1726-9776-2023-19-3-153-162

K. Titov, E. V. Shutov, A. A. Alimov, S. S. Lebedev, A. Kirichek, G. M. Zapirov

引用次数: 0

Cytoreductive nephrectomy and its effect on prognosis in patients with disseminated renal cell carcinoma receiving treatment in wide clinical practice 广泛临床实践中接受治疗的播散性肾细胞癌患者的细胞切除肾切除术及其对预后的影响

Cancer Urology Pub Date : 2023-11-15 DOI: 10.17650/1726-9776-2023-19-3-31-44

D. V. Semenov, R. V. Orlova, V. Shirokorad, S. V. Kostritskiy, M. Gluzman, Y. Korneva

{"title":"Cytoreductive nephrectomy and its effect on prognosis in patients with disseminated renal cell carcinoma receiving treatment in wide clinical practice","authors":"D. V. Semenov, R. V. Orlova, V. Shirokorad, S. V. Kostritskiy, M. Gluzman, Y. Korneva","doi":"10.17650/1726-9776-2023-19-3-31-44","DOIUrl":"https://doi.org/10.17650/1726-9776-2023-19-3-31-44","url":null,"abstract":"Aim. To evaluate the effect of cytoreductive nephrectomy (CN) on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) and to identify a group of patients who are candidates for cytoreductive surgical treatment.Materials and methods. We retrospectively analyzed a database of 403 patients with mRCC treated at the Moscow City Oncological Hospital No. 62 and the City Clinical Oncological Dispensary (Saint Petersburg) between 2006 and 2022. In total, 330 (81.9 %) patients underwent CN. All patients received systemic anti-tumor therapy: targeted anti-angiogenic therapy - 317 (78.6 %), cytokines - 61 (15.1 %), checkpoint inhibitors - 25 (6.2 %). The groups of operated and non-operated patients were unbalanced: CN was more often not performed in patients with multiple metastases, bone and liver lesions, laboratory abnormalities (anemia, increased serum alkaline phosphatase and lactate dehydrogenase) and unfavorable prognosis per IMDC (International mRCC Database Consortium) classification (p >0.05 for all). Results. CN was associated with a significant increase in OS compared with primary tumor preservation in situ: median OS was 36 months with 95 % confidence interval 29.1-37.1, and 11 months with 95 % confidence interval 8.1-21.3, respectively (p <0.0001). The benefit for OS in the CN group was also observed in clear-cell mRCC (p <0.0001), grade G3 (p <0.0001), multiple metastases (p <0.0001) groups, and in the IMDC poor prognosis group (p <0.0001). Conclusion. CN in selected mRCC patients results in a significant increase in OS. Further research is needed to determine selection criteria for surgical treatment candidates.","PeriodicalId":216890,"journal":{"name":"Cancer Urology","volume":"2 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139273068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acute kidney injury and its predictors in surgery of malignant kidney tumors 恶性肾肿瘤手术中的急性肾损伤及其预测因素

Cancer Urology Pub Date : 2023-11-15 DOI: 10.17650/1726-9776-2023-19-3-19-28

K. Pozdnyakov, S. Rakul, R. Eloev, K. A. Lukinov

{"title":"Acute kidney injury and its predictors in surgery of malignant kidney tumors","authors":"K. Pozdnyakov, S. Rakul, R. Eloev, K. A. Lukinov","doi":"10.17650/1726-9776-2023-19-3-19-28","DOIUrl":"https://doi.org/10.17650/1726-9776-2023-19-3-19-28","url":null,"abstract":"Aim. To analyze our own results of the course of early postoperative period in patients who underwent surgical treatment of kidney tumors: partial nephrectomy (PN) and radical nephrectomy (RN) and to identify risk factors for the development of acute kidney injury (AKI).Materials and methods. The study included 399 patients, of which 276 patients (69.17 %) underwent PN, 123 (30.83 %) underwent RN. According to the clinical stage of the disease, patients in the PN and RN groups were distributed as follows: cT1a – 160 (91.95 %) and 14 (8.05 %), cT1b – 99 (61.11 %) and 63 (38.89 %) and cT2a – 17 (26.98 %) and 46 (73.02 %), respectively. Operations were performed with open (1.0 %), laparoscopic (39.35 %) and robot-assisted (59.65 %) accesses. AKI was evaluated by the changes in serum creatinine and glomerular filtration rate before surgery and 1–3 days after in accordance with KDIGO criteria.Results. The overall incidence of AKI after surgical treatment for kidney cancer at stages cT1a–cT2a was 27.57 %. The incidence of AKI after RN was 65.04 %, after PN – 11.23 %. At stages cT1a, cT1b, cT2a, after nephron-sparing surgery and radical treatment, this indicator was 9.37; 11.11; 29.41 % and 71.43; 63.49; 65.22 %, respectively. For warm ischemia time below 15 and 20 minutes, AKI incidence did not exceed 8.3 and 13.2 %, respectively. For warm ischemia time >30 min, a dramatic increase in AKI incidence was observed.Conclusion. To preserve kidney function, PN is the operation of choice in surgical treatment of kidney tumors at stages cT1–cT2a. After RN, AKI development was observed 6 times more often than after PN. The following statistically significant predictors of AKI after PN were identified: presence of initial chronic kidney disease in patients, tumor size, operative time above 190 minutes, type of kidney ischemia used, and warm ischemia time above 25 minutes.","PeriodicalId":216890,"journal":{"name":"Cancer Urology","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139273193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical use of high dose-rate brachytherapy in treatment of patients with localized prostate cancer and infravesical obstruction 高剂量率近距离放射疗法在治疗局部前列腺癌和尿道下段梗阻患者中的临床应用

Cancer Urology Pub Date : 2023-11-15 DOI: 10.17650/1726-9776-2023-19-3-60-68

D. M. Yagudaev, A. G. Martov, D. V. Ergakov, D. D. Yagudaev, Z. A. Kadyrov

{"title":"Clinical use of high dose-rate brachytherapy in treatment of patients with localized prostate cancer and infravesical obstruction","authors":"D. M. Yagudaev, A. G. Martov, D. V. Ergakov, D. D. Yagudaev, Z. A. Kadyrov","doi":"10.17650/1726-9776-2023-19-3-60-68","DOIUrl":"https://doi.org/10.17650/1726-9776-2023-19-3-60-68","url":null,"abstract":"Background. High dose-rate brachytherapy is a new method of interstitial radiation therapy for treatment of localized prostate cancer. The difference from low dose therapy is temporary implantation of radiation sources with targeted high dose-rate irradiation of the affected organ.Aim. To evaluate 3-year effectiveness and safety of high dose-rate brachytherapy in patients with infravesical obstruction. Materials and methods. Between January of 2017 and December of 2019 at the Central Clinical Hospital “RZD-medicine”, 49 patients (mean age 67.8 ± 7.5 years) with verified prostate cancer diagnosis underwent high dose-rate brachytherapy in the regimen of 2 sessions of 15 Gy with 192Ir source. The inclusion criteria were disease stage ≤сТ2с, Gleason score ≤7. Patients were divided into 2 groups: 1st – patients with incidental prostate cancer (n = 21) who previously (more than 6 months ago, mean time 9.4 ± 2.4 months) underwent transurethral prostatectomy; 2nd – patients with verified prostate cancer (mean prostate volume 56 cm3) and obstructive symptoms without previous transurethral prostatectomy (n = 28).Results. In both groups, no intraoperative complications were observed. In 6 (28 %) patients of the 1st group and 2 patients of the 2nd group, grade II genitourinary toxicity in the form of moderate dysuria and nocturia was observed. Acute gastrointestinal toxicity was observed in 3 (14 %) patients of the 1st group, in the 2nd group such complications were absent. In the 2nd group during the postoperative period after the 2nd session, 4 patients (14 %) experienced acute urinary retention requiring cystostomy.Conclusion. High dose-rate brachytherapy is a safe and effective radical treatment method for patients with localized prostate cancer with obstructive symptoms who have contraindications for surgical treatment.","PeriodicalId":216890,"journal":{"name":"Cancer Urology","volume":"10 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139274452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Radical prostatectomy in the Russian Federation: features of perioperative management and nuances of technical execution 俄罗斯联邦的根治性前列腺切除术：围手术期管理的特点和技术执行的细微差别

Cancer Urology Pub Date : 2023-11-15 DOI: 10.17650/1726-9776-2023-19-3-45-59

N. Gadzhiev, V. A. Rybalchenko, I. B. Dzhalilov, D. D. Shkarupa, A. Shkarupa, I. Semeniakin, S. B. Petrov

引用次数: 0